Synonyms: BPN-19186 | BPN19186 | EC-5026
Compound class:
Synthetic organic
Comment: EC5026 is a first-in-class, orally active soluble epoxide hydrolase (sEH; epoxide hydrolase 2; EPHX2) inhibitor [1]. It was designed fo treat inflammatory and neuropathic pain.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
EC5026 was advanced to clinical studies. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04228302 | Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects | Phase 1 Interventional | EicOsis Human Health Inc. |